Apogee Therapeutics, Inc.
Clinical trials sponsored by Apogee Therapeutics, Inc., explained in plain language.
A biotech company developing antibody therapies for inflammatory and immunologic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New asthma drug enters early human testing Results expected Sep 2026 (estimated)
- New eczema drug shows promise in Mid-Stage trial Results expected Nov 2026 (estimated)
-
New eczema drug combo enters early human testing
Disease control OngoingThis early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixe…
Phase 1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief OngoingThis study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…
Phase 2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
New asthma drug enters early human testing
Symptom relief OngoingThis early-stage study tests a new drug called APG777 in 31 adults with mild-to-moderate asthma. The main goal is to check if the drug is safe and how the body handles it. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug…
Phase 1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC